BrickBio

BrickBio is a private, preclinical-stage biotech based in Cambridge, MA, founded in 2019. The company's core innovation is the Evolved tRNA Localization (ETRNAL) Platform, a mammalian expression system that enables efficient, site-specific incorporation of synthetic amino acids as conjugation handles into any protein backbone. This technology is designed to overcome the heterogeneity and instability of traditional conjugation methods, with initial applications in creating superior ADCs and multi-payload conjugates that are safer and more efficacious. BrickBio operates as a platform company, likely pursuing both internal therapeutic programs and external partnerships.

Evolved tRNA Localization (ETRNAL) Platform: a mammalian expression system using engineered tRNA to enable site-specific, homogeneous incorporation of synthetic amino acid conjugation handles into any protein backbone. Includes a proprietary Site-Selection Panel Algorithm for optimal conjugation site prediction and enables diverse chemistries like eCLIC™.

BrickBio competes in the site-specific bioconjugation space with companies like Ambrx, Ajinomoto Bio-Pharma Services, and Synaffix (acquired by Lonza). Its differentiation lies in the efficiency of its ETRNAL Platform, its proprietary site-prediction algorithm, and its focus on accessing previously inaccessible, optimized conjugation sites to create conjugates with superior biophysical properties.